Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/21/2784430/15114/en/Lumos-Pharma-to-Host-Virtual-Key-Opinion-Leader-Webinar-to-Discuss-Phase-2-OraGrowtH-Trial-Data-and-Treatment-Potential-of-Oral-LUM-201-for-Pediatric-Growth-Hormone-Deficiency.html

AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail. Management will be joined by three esteemed thought leaders in the field of endocrinology:

Read more at globenewswire.com

Related news for (LUMO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.